PZPaola Zangari

Paola Zangari

*This is an algorithmically generated author record based on publicly available information.

Paola Zangari has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Paolo Palma

    Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

    4 shared publications
  • Andrea Finocchi

    Clinical and Research Unit of Clinical Immunology and Vaccinology Bambino Gesù Children's Hospital, IRCCS Rome Italy

    3 shared publications
  • Caterina Cancrini

    Clinical and Research Unit of Clinical Immunology and Vaccinology Bambino Gesù Children's Hospital, IRCCS Rome Italy

    3 shared publications
  • Donato Amodio

    Clinical Immunology and Vaccinology Unit Bambino Gesù Children's Hospital IRCCS Rome Italy

    3 shared publications
  • Nicola Cotugno

    Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

    3 shared publications
  • Andrea Diociaiuti

    Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division Bambino Gesù Children's Hospital, IRCCS Rome Italy

    2 shared publications

Latest Publications

  • Open Access

    Use of Dupilumab in Pediatric Atopic Dermatitis and in Inborn Errors of Immunity-Associated Atopic Skin Disease: An Italian Society of Pediatric Research (SIRP) Multicenter Real-World Study

    by Mayla Sgrulletti, Maddalena Napolitano, Emilia Cirillo, Donato Amodio, Paola Zangari, Elisabetta Del Duca, Elena Galli, Irene Berti, Laura Diluvio, Luca Bianchi, et al.

    Background: Atopic dermatitis (AD) is generally considered polygenic but may occur as a predominant manifestation of inborn errors of immunity (IEI). Although dupilumab is effective in pediatric AD, evidence in IEI-associated severe atopic skin disease remains limited, with no longitudinal comparative studies available. We aimed to characterize clinical phenotype and compare effectiveness, quality-of-life, and safety of dupilumab in pediatric patients with severe polygenic AD and IEI-associated severe atopic skin disease. Methods: This multicenter retrospective observational study within the Italian Society of Pediatric Research Network included children and adolescents who initiated dupilumab before 18 years of age. Given IEI rarity, we accepted a numerically unbalanced but clinically meaningful cohort. Clinical outcomes were assessed longitudinally using EASI, pruritus NRS, and CDLQI scores. Achievement and maintenance of EASI-50/75/90 re-sponses were evaluated, together with adverse events and treatment discontinuation. Results: Among 127 patients, 116 had polygenic AD and 11 had IEI-associated disease. IEI patients more frequently had disease onset within 6 months (64% vs. 29%; p=0.037), severe recurrent infections (100% vs. 0%; p< 0.001), very elevated sIgE (91% vs. 14%; p< 0.001), and higher baseline EASI (median 50 vs. 25; p< 0.001). EASI, pruritus, and CDLQI improved significantly over time. EASI-50/75/90 were achieved by 88.2%/81.9%/66.1% and maintained by 84.3%/69.3%/47.2%. IEI patients showed steeper EASI decline but achieved EASI-75/90 later. Dupilumab was well tolerated with no unexpected safety signals. Conclusions: Dupilumab provided rapid, sustained improvement across both groups. Despite greater baseline severity and slower deep clearance achievement, IEI patients demonstrated substantial durable benefit, supporting dupilumab use in selected IEI-associated atopic manifestations.

  • Open Access

    Pre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response

    by Paolo Palma, Elena Emili, Chiara Pighi, Nicole Colantoni, Elena Morrocchi, Giuseppe Rubens Pascucci, Beatrice Rivalta, Gioacchino Andrea Rotulo, Chiara Rossetti, Veronica Santilli, et al.

    The emergence of SARS-CoV-2 in late 2019 led to a global pandemic, prompting unprecedented efforts to develop and deploy effective vaccines.1–3 The BNT162b2 mRNA COVID-19 vaccine has demonstrated h...

  • Open Access

    Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity

    by Paola Zangari, Carmela Giancotta, Lucia Pacillo, Nicole Colantoni, Fabrizio Leone, Donato Amodio, Veronica Santilli, Emma Concetta Manno, Nicola Cotugno, Beatrice Rivalta, et al.


  • Open Access

    Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement

    by Carmela Giancotta, Nicole Colantoni, Lucia Pacillo, Veronica Santilli, Donato Amodio, Emma Concetta Manno, Nicola Cotugno, Gioacchino Andrea Rotulo, Beatrice Rivalta, Andrea Finocchi, et al.

    Inborn errors of immunity associated with atopy (IEIs-A) are a group of inherited monogenic disorders that occur with immune dysregulation and frequent skin involvement. Several pathways are involved in the pathogenesis of these conditions, including immune system defects, alterations of skin barrier and metabolism perturbations. Current technological improvements and the higher accessibility to genetic testing, recently allowed the identification of novel molecular pathways involved in IEIs-A, also informing on potential tailored therapeutic strategies. Compared to other systemic therapy for skin diseases, biologics have the less toxic and the best tolerated profile in the setting of immune dysregulation. Here, we review IEIs-A with skin involvement focusing on the tailored therapeutic approach according to their pathogenetic mechanism.


  • Open Access

    In Search for the Missing Link in APECED-like Conditions: Analysis of the AIRE Gene in a Series of 48 Patients

    by Alessandra Fierabracci, Eugenia Belcastro, Elena Carbone, Olivia Pagliarosi, Alessia Palma, Lucia Pacillo, Carmela Giancotta, Paola Zangari, Andrea Finocchi, Caterina Cancrini, et al.

    Autoimmune diseases are a heterogeneous group of disorders of the immune system. They can cluster in the same individual, revealing various preferential associations for polyendocrine autoimmune syndromes. Clinical observation, together with advances in genetics and the understanding of pathophysiological processes, has further highlighted that autoimmunity can be associated with immunodeficiency; autoimmunity may even be the first primary immunodeficiency manifestation. Analysis of susceptibility genes for the development of these complex phenotypes is a fundamental issue. In this manuscript, we revised the clinical and immunologic features and the presence of AIRE gene variations in a cohort of 48 patients affected by high polyautoimmunity complexity, i.e., APECED-like conditions, also including patients affected by primary immunodeficiency. Our results evidenced a significant association of the S278R polymorphism of the AIRE gene with APECED-like conditions, including both patients affected by autoimmunity and immunodeficiency and patients with polyautoimmunity compared to healthy controls. A trend of association was also observed with the IVS9+6 G>A polymorphism. The results of this genetic analysis emphasize the need to look for additional genetic determinants playing in concert with AIRE polymorphisms. This will help to improve the diagnostic workup and ensure a precision medicine approach to targeted therapies in APECED-like patients.


  • Open Access

    Novel Compound Heterozygous Mutations in IL-7 Receptor α Gene in a 15-Month-Old Girl Presenting With Thrombocytopenia, Normal T Cell Count and Maternal Engraftment

    by Paola Zangari, Cristina Cifaldi, Silvia Di Cesare, Gigliola Di Matteo, Maria Chiriaco, Donato Amodio, Nicola Cotugno, Maia De Luca, Cecilia Surace, Saverio Ladogana, et al.

    Patients with severe combined immunodeficiency (SCID) exhibit T lymphopenia and profound impairments in cellular and humoral immunity. IL-7 receptor α (IL-7Rα) deficiency is a rare form of SCID that usually presents in the first months of life with severe and opportunistic infections, failure to thrive and high risk of mortality unless treated. Here, we reported an atypical and delayed onset of IL7Rα-SCID in a 15-month-old girl presenting with thrombocytopenia. Immunological investigations showed a normal lymphocyte count with isolated CD4-penia, absence of naïve T cells, marked hypergammaglobulinemia, and maternal T cell engraftment. Targeted next generation sequencing (NGS) revealed two novel compound heterozygous mutations in the IL-7Rα gene: c.160T>C (p.S54P) and c.245G>T (p.C82F). The atypical onset and the unusual immunological phenotype expressed by our patient highlights the diagnostic challenge in the field of primary immunodeficiencies (PID) and in particular in SCID patients where prompt diagnosis and therapy greatly affects survival.


  • Open Access

    Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy

    by C. Ciarlitto, A. C. Vittucci, L. Antilici, C. Concato, C. Di Camillo, P. Zangari, A. Villani

    Respiratory syncytial virus (RSV) is the main cause of hospitalization for bronchiolitis among infants. RSV is classified into two subtypes, A and B, whose predominance alternates during different epidemic seasons. The clinical impact of viral factors is controversial and many evidences suggest a critical role for the immune host response. Premature children are at the highest risk for severe RSV infection. The main aim of this study is to identify the different RSV subtypes circulating in the last three epidemic seasons and to evaluate whether any of them was associated with poor prognosis in term and preterm infants. We performed a retrospective analysis of medical records for all patients aged less than one year which were hospitalized during the winter season between November 2015 and April 2018 with clinical diagnosis of bronchiolitis and nasopharyngeal aspirates positive for RSV. We enrolled 422 children, of which 50 were born preterm. During the analysis period, we observed a significant increase in the rates of oxygen supplementation and admission to intensive care unit. The evidence shows an alternating pattern in the prevalence of RSV subtypes among term born; in each epidemic season, the prevalent serotype is the cause of the majority of the cases requiring intensive care. Conversely, RSV-A is always prevalent in preterm children and caused most of the cases requiring intensive care. During the 3 seasons analyzed, we observed an alternating prevalence of RSV A and B. While there are no differences in severity between RSV A and B in term population, RSV-A is prevalent and causes most of the severe cases in the premature group. Furthermore, an increase in RSV-related oxygen therapy and PICU admission has been documented not only in the premature population. Considering the absence of appropriate therapeutic strategies, our work emphasizes the importance of implementing prophylaxis measures against RSV and highlights the urgent need to gain knowledge about immune response to the virus, also in premature children.


  • Top Cited Papers
    Open Access

    Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART

    by Sonia Zicari, Libera Sessa, Nicola Cotugno, Alessandra Ruggiero, Elena Morrocchi, Carlo Concato, Salvatore Rocca, Paola Zangari, Emma C. Manno, Paolo Palma

    Despite effective antiretroviral therapy (ART), people living with HIV (PLWH) still present persistent chronic immune activation and inflammation. This condition is the result of several factors including thymic dysfunction, persistent antigen stimulation due to low residual viremia, microbial translocation and dysbiosis, caused by the disruption of the gut mucosa, co-infections, and cumulative ART toxicity. All of these factors can create a vicious cycle that does not allow the full control of immune activation and inflammation, leading to an increased risk of developing non-AIDS co-morbidities such as metabolic syndrome and cardiovascular diseases. This review aims to provide an overview of the most recent data about HIV-associated inflammation and chronic immune exhaustion in PLWH under effective ART. Furthermore, we discuss new therapy approaches that are currently being tested to reduce the risk of developing inflammation, ART toxicity, and non-AIDS co-morbidities.